The clinical benefit of first-line pembrolizumab monotherapy in patients with PD-L1-positive and EGFR/ALK wild-type advanced NSCLC was confirmed in the multicenter, randomized, open-label, controlled phase III study KEYNOTE-042 (34). This evidence concerns the gene CD274 and non-small cell lung carcinoma.